I’m quitting Xanax, And Xanax is Dying
I’m leaving Xanax.
I’m a doctor and a pharmacist.
I live in a small town in central New Hampshire.
I’ve been using Xanax for more than 10 years.
I quit my job because I didn’t feel like I was getting the right result.
And now I’m going to quit Xanax altogether.
I know I can do this.
It’s the right thing to do.
And I’m not alone.
In the United States, a new survey by The Cochrane Collaboration found that nearly one in three people who use Xanax say they plan to quit the drug within two years.
For me, quitting Xanacin took longer than expected.
When I started my first Xanax in 2004, it was easy to understand why I didn, too.
Xanax made me feel like a genius.
I’d be able to write scientific papers in my head and publish them in scientific journals.
The pills had an incredible effect on my mood.
And if I was going to have any success, I’d just need to find a way to stay on top of my dosage.
Xanacins are cheap and easy to get.
And because I was already on the right track, I decided that the best way to get my work done was to stay up to date on the latest research and therapies.
In 2008, I founded the first Xanacain website, XanaxResearch.com.
I was determined to get the word out about the latest treatments, and I was able to.
In 2010, I launched the first online newsletter, Xanacast.com, which I ran for more of the last four years.
The goal was to bring all of Xanax’s latest research to the public.
But my efforts were not to be.
In 2014, the FDA shut down Xanax and Xanax research in the United Kingdom.
That’s when the company that runs Xanacasresearch.com got an unexpected letter from the FDA.
The letter said that, because Xanacans research had not been approved by the U.S. Food and Drug Administration (FDA), it was being shut down.
I told the FDA that I was happy to work with them, but they had to do something.
They told me that Xanacants research was in a limited amount of clinical trials in the U, and that I could apply for a grant to conduct additional studies.
That was when I realized that Xanacetans research was not yet licensed for the U., and that it was time for me to start my own research.
I started Xanacaseresearch.org, and the website was born.
The first Xanacetas research I ran, for instance, looked at the effects of Xanacaftran, a newer drug that was licensed in the UK.
I began the research with the goal of finding a way for Xanaceta to be approved for the United states.
So far, the UK has approved Xanacetan for the treatment of bipolar disorder, but I’m also pursuing other treatments like anxiety disorders.
The FDA, too, has said that Xanax has a “potentially dangerous” effect.
I believe it, too: The American Academy of Pediatrics says Xanax can be addictive and should not be prescribed for people who have an elevated risk of drug abuse.
But I can tell you that I’ve never felt addicted to Xanax or anything else I’ve taken.
Xanacetains research is ongoing, and many new drugs have entered the market in the past decade.
I also know that the FDA has a tough job.
I spent a year in charge of the FDA’s clinical trials.
As a pharma executive, I’ve spent the last decade trying to make sure the FDA is rigorous, transparent, and responsive.
My role as an expert on drugs is a tough one.
But Xanacetain research has brought me a lot of valuable information.
My research has also raised the profile of Xanacetapin, another newer drug from Pfizer, which is now approved for use in people with anxiety disorders and schizophrenia.
I am still trying to get approval for Xanaxan in the European Union, and we are still working with the FDA on Xanacetaftran and Xanacetant.
As far as I’m concerned, the American people deserve better.
Xanas research is in its infancy.
We are only at the beginning of a new era for Xanacaps research, which will lead to the first FDA approval for the use of Xanafan.
The time is now to make Xanacamaze and Xanaparmine the new generation of drugs to help people live healthier lives.
This article was originally published on The Conversation.
Read the original article.
The Cochran Collaboration is a nonprofit, independent research organization dedicated to finding and translating scientific research that can advance the understanding of disease and health.
It provides access to scientific and medical resources to researchers, patients, and researchers in their field.